BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18634839)

  • 1. Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles.
    Bowman K; Sarkar R; Raut S; Leong KW
    J Control Release; 2008 Dec; 132(3):252-9. PubMed ID: 18634839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophilia A mice.
    Dhadwar SS; Kiernan J; Wen J; Hortelano G
    J Thromb Haemost; 2010 Dec; 8(12):2743-50. PubMed ID: 20961391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
    Quade-Lyssy P; Milanov P; Abriss D; Ungerer C; Königs C; Seifried E; Schüttrumpf J
    J Thromb Haemost; 2014 Jun; 12(6):932-42. PubMed ID: 24679056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.
    Quade-Lyssy P; Abriss D; Milanov P; Ungerer C; Königs C; Seifried E; Schüttrumpf J
    J Thromb Haemost; 2014 Nov; 12(11):1861-73. PubMed ID: 25224783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
    Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
    Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system.
    Ohlfest JR; Frandsen JL; Fritz S; Lobitz PD; Perkinson SG; Clark KJ; Nelsestuen G; Key NS; McIvor RS; Hackett PB; Largaespada DA
    Blood; 2005 Apr; 105(7):2691-8. PubMed ID: 15576475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response.
    Ozelo MC; Vidal B; Brown C; Notley C; Hegadorn C; Webster S; Harpell L; Ahlin J; Winterborn A; Handforth J; Arruda VR; Hough C; Lillicrap D
    Blood; 2014 Jun; 123(26):4045-53. PubMed ID: 24829206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice.
    Damon AL; Scudder LE; Gnatenko DV; Sitaraman V; Hearing P; Jesty J; Bahou WF
    Thromb Haemost; 2008 Dec; 100(6):1111-22. PubMed ID: 19132238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.
    Kang Y; Xie L; Tran DT; Stein CS; Hickey M; Davidson BL; McCray PB
    Blood; 2005 Sep; 106(5):1552-8. PubMed ID: 15886327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
    Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.
    Siner JI; Iacobelli NP; Sabatino DE; Ivanciu L; Zhou S; Poncz M; Camire RM; Arruda VR
    Blood; 2013 May; 121(21):4396-403. PubMed ID: 23372167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice.
    VandenDriessche T; Vanslembrouck V; Goovaerts I; Zwinnen H; Vanderhaeghen ML; Collen D; Chuah MK
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10379-84. PubMed ID: 10468616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the Potential Feasibility of Intra-Articular Adeno-Associated Virus-Mediated Gene Therapy for Hemophilia Arthropathy.
    Zhang F; Yan X; Li M; Hua B; Xiao X; Monahan PE; Sun J
    Hum Gene Ther; 2020 Apr; 31(7-8):448-458. PubMed ID: 32079420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A.
    Matsui H; Fujimoto N; Sasakawa N; Ohinata Y; Shima M; Yamanaka S; Sugimoto M; Hotta A
    PLoS One; 2014; 9(8):e104957. PubMed ID: 25126862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet and endothelial expression of clotting factors for the treatment of hemophilia.
    Montgomery RR; Shi Q
    Thromb Res; 2012 May; 129 Suppl 2(Suppl 2):S46-8. PubMed ID: 22421106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.
    Staber JM; Pollpeter MJ; Anderson CG; Burrascano M; Cooney AL; Sinn PL; Rutkowski DT; Raschke WC; McCray PB
    Gene Ther; 2017 Nov; 24(11):742-748. PubMed ID: 28905885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy.
    Connelly S; Andrews JL; Gallo AM; Kayda DB; Qian J; Hoyer L; Kadan MJ; Gorziglia MI; Trapnell BC; McClelland A; Kaleko M
    Blood; 1998 May; 91(9):3273-81. PubMed ID: 9558383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A.
    Saenko EL; Ananyeva NM; Moayeri M; Ramezani A; Hawley RG
    Curr Gene Ther; 2003 Feb; 3(1):27-41. PubMed ID: 12553533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
    Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
    Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.